SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after breaking to new all-time highs fueled by strong institutional demand and positive sentiment surrounding its data center CPU growth and potential hardware partnerships with frontier AI labs. The community remains deeply divided, with bulls pointing to the company's expanding role in AI compute and agentic workflows, while vocal bears argue the rapid momentum is detached from fundamentals and represents an overextended bubble.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing significant volatility as investors react to a Q1 earnings beat that was overshadowed by a disappointing Q2 guidance miss and the departure of co-founder Reed Hastings from the board. The community is sharply divided, with many debating whether the drop presents a prime buying opportunity for a long-term profit machine or if structural concerns and leadership changes signal an end to its aggressive growth era.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing significant volatility and surging volume as investors react to reports of a pending executive order that would prioritize federal research into the therapeutic use of ibogaine for PTSD. The community is heavily focused on the stock's extremely low float and its potential to spark a massive short squeeze, with active debates continuing over the legitimacy of the catalyst versus concerns regarding the company's history of reverse splits and dilution.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently locked in a tug-of-war at the 75k resistance level, with sentiment split between retail traders bracing for a potential breakout and skeptics questioning its correlation to traditional markets. Community discussions are heavily focused on the impact of upcoming legislative acts, institutional buying pressure from ETFs, and the ongoing debate surrounding geopolitical developments as potential catalysts for the next major move.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor heightened geopolitical focus on Greenland's strategic rare earth deposits and the potential for domestic supply chain mandates. The community is actively debating the project's long-term economic potential while speculating on the impact of upcoming pilot plant results and broader U.S.-led critical mineral trade policies.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a surge in investor interest driven by a strategic pivot into AI foundry services, fueled by partnerships with major hyperscalers like Google and potential infrastructure collaborations involving the broader Tesla ecosystem. While the community is actively debating the stock's recent rapid valuation expansion, sentiment remains divided between those betting on long-term foundry turnaround potential and others cautioning against momentum-driven overvaluation ahead of upcoming earnings.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

BUTTCOIN is trending as the community rallies around its status as the original 2011 internet satire, positioning it as an authentic, long-standing historical asset rather than just another fleeting meme. Investors are actively debating its longevity and potential for a multi-billion-dollar valuation, with many pointing to locked supply and historical roots as key drivers for their conviction.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors closely watch for upcoming fiscal year guidance and backlog updates, with the community actively debating the company's valuation as a foundational software provider for software-defined vehicles. Sentiment remains divided between long-term believers who are focused on the expansion of QNX into robotics and defense, and those expressing frustration over past stock performance and management execution.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending as investors debate its pivot toward becoming a high-scale AI infrastructure provider, with community members actively highlighting the potential of its large-scale energy capacity as a competitive advantage. Despite this, some investors remain skeptical, citing high short interest and management's past share dilution as key concerns while they monitor the stock's ability to hold onto recent price gains.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing significant market focus ahead of its quarterly earnings release as investors scrutinize its ability to navigate supply-chain constraints and memory chip shortages. The community is actively debating the stock's long-term potential in data center and edge AI versus near-term handset headwinds, with many traders closely monitoring the volatile price action and options activity leading up to the report.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The 10-day ceasefire between Israel and Lebanon has gone into effect, while President Donald Trump struck an optimistic tone on the resolution with Iran.</li><li>Markets are beginning to price in de-escalation in the Middle East, sending crude below $100 and nudging equities higher.</li><li>Netflix slumped on weak guidance, while Nvidia remains under scrutiny amid rising skepticism despite its AI leadership.</li></ul>U.S. stock futures&nbsp;rose early Friday as investors weighed the likelihood of a resolution to the Middle East crisis. A 10-day ceasefire is in effect between Israel and Lebanon.&nbsp;Meanwhile, President Donald Trump on Thursday stated the war in Iran “should be ending pretty soon” and described negotiations as “going along swimmingly,” to reopen the Strait of Hormuz. Both countries are expected to resume peace talks over the weekend. Crude oil prices fell below $100/barrel on easing geopolitical tensions, while defense-linked companies found favor among investors.As of 4:00 a.m. ET on Friday, Dow futures rose 0.3%, S&amp;P 500 futures gained 0.1%, Nasdaq futures were flat, and Russell 2000 futures were up 0.2%.&nbsp;Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has flipped to ‘extremely bullish,’ a sharp move from the ‘bearish’ sentiment earlier this week.&nbsp;Trending Stocks To WatchNetflix (NFLX):&nbsp;Shares fell nearly 10% in early pre-market trade following a disappointing forecast and the news that co-founder Reed Hastings will exit the board in June. However, CEO Ted Sarandos highlighted that the company’s cash position remains elevated following the failed bid for Warner Bros.&nbsp;Psyence Biomedical (PBM):&nbsp;The stock is attracting heavy retail attention on reports that the White House is preparing an executive order to support further federal research into the psychedelic compound ibogaine.WeShop Holdings (WSHP):&nbsp;The stock has nearly quadrupled in value over the past five sessions and is on track to log its best&nbsp;weekly performance since late November. Retail interest is surging ahead of its results, which are due later this month.&nbsp;Nvidia (NVDA):&nbsp;The AI giant remained under scrutiny after ‘The Big Short’ investor Michael Burry criticized CEO Jensen Huang’s recent podcast appearance. Burry claimed that Huang ‘squirmed and obfuscated’ when questioned about the company’s long-term moat and geopolitical risks.Hims &amp; Hers Health (HIMS):&nbsp;Shares have been gaining attention this week, with new signals from the U.S. Food and Drug Administration (FDA) suggesting that its testosterone therapy could be the next growth driver for this telehealth firm.Defense IPO Watch:&nbsp;Drone maker AEVEX (AVEX) raised $320 million in its IPO, pricing at $20 per share, and is set to debut on the NYSE today. Meanwhile, Arxis (ARXS) soared 36% in its Nasdaq debut on Thursday.AST SpaceMobile (ASTS)&nbsp;has confirmed the BlueBird 7 launch for Sunday, April 19.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Verizon (VZ), Iren Limited (IREN), Sidus Space (SIDU), and Rumble Inc (RUM).&nbsp;Other Catalysts To WatchOn the economic front, no notable data release is expected. Traders will be watching commentary from a host of Fed speakers throughout the day, including Richmond Fed President Tom Barkin and Fed Governor Christopher Waller.&nbsp;On earnings radar, watch out for quarterly reports from&nbsp;Fifth Third Bancorp (FITB), State Street (STT), Regions Financial (RF), Ally Financial (ALLY), Truist (TFC), and reAlpha Tech Corp (AIRE), among others, today.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Rise With ‘War Trade’ Unwinding: Why NFLX, WSHP, PBM, HIMS, NVDA Are Keeping Traders Engaged Today

Data from Stocktwits shows that retail positioning has shifted decisively from bearish sentiment earlier this week for SPY and QQQ. 

Equity

Data from Stocktwits shows that retail positioning has shifted decisively from bearish sentiment earlier this week for SPY and QQQ. 


<ul class="summary-bullets"><li>The FDA signaled openness to expanding testosterone therapy use for low libido linked to idiopathic hypogonadism, a condition without a known cause.</li><li>Hims began building its testosterone-care platform in September 2025, allowing providers to prescribe enclomiphene-based treatment and combination therapy.</li><li>BofA turned bullish on Hims, citing potential upside from upcoming July FDA advisory committee meetings reviewing peptide substances for inclusion on the 503A Bulks List.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) have been riding a strong rally on peptide and weight-loss treatment momentum, but a fresh signal from the U.S. Food and Drug Administration (FDA) suggests the telehealth firm’s testosterone therapy could be emerging as the company’s next major growth pillar.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> jumped over 11% on Thursday, logging its fourth straight session of gains. Shares are headed&nbsp;for their best week in over a month.<h2 class="st-heading-2">FDA Opens Door To Broader Testosterone Therapy Use</h2>The FDA said on Thursday that it is encouraging sponsors of approved testosterone replacement therapy (TRT) products to contact the agency if they are interested in pursuing a potential new indication for treating low libido in men with idiopathic hypogonadism, a form of low testosterone without a known cause.&nbsp;The agency said the development follows a preliminary review of published clinical literature and a discussion at a December 2025 expert panel meeting, which identified evidence suggesting TRT may be safe and effective for certain men in this population.&nbsp;However, sponsors would still need to submit “substantial evidence” of clinical data showing that the benefits outweigh risks, and the FDA has asked interested companies to initiate discussions by April 30.Currently, FDA-approved TRT therapies are indicated only for men with hypogonadism linked to identifiable medical causes. TRT is used to restore hormone levels in men with low testosterone, a condition that can affect energy, mood, libido, bone density, and muscle strength, and is typically delivered through injections, gels, patches, or oral formulations.<h2 class="st-heading-2">Hims’ Testosterone Care Push&nbsp;</h2>Hims said in September 2025 that providers on its platform can prescribe personalized doses of compounded enclomiphene, a treatment that helps the body restore natural testosterone levels without affecting fertility. For men experiencing sexual-health symptoms linked to low testosterone, the company also introduced combination treatment options that pair enclomiphene with tadalafil, a commonly used erectile dysfunction medication.The company had also announced plans to expand further into testosterone care this year through exclusive access to the approved oral testosterone therapy Kyzatrex under a partnership with Marius Pharmaceuticals, with injectable testosterone options expected to follow.<h2 class="st-heading-2">Wall Street Flags Peptide Policy Tailwind</h2>The testosterone catalyst is emerging alongside regulatory developments in peptide access, which analysts say could drive additional growth opportunities for the company’s platform.Bank of America Securities (BofA) recently raised its price target on Hims &amp; Hers, citing potential upside from upcoming FDA advisory committee meetings in July that will review peptide substances for possible inclusion on the federal 503A Bulks List. A favorable outcome could allow the company to repurpose its existing GLP-1 infrastructure for additional peptide therapies as it transitions to branded weight-loss medicines, BofA said.&nbsp;Separately, Leerink called the recent regulatory progress around peptide access a “clear positive” for Hims &amp; Hers, saying any easing of restrictions could help “fill the growth hole” expected as the company shifts away from compounded obesity treatments. The brokerage added that a favorable advisory committee recommendation could allow Hims &amp; Hers to leverage its existing peptide facility.<h2 class="st-heading-2">How Do Retail Traders Feel About HIMS?</h2>On Stocktwits, retail sentiment was ‘extremely bullish’ amid nearly a 700% surge in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_79debd59a3.webp" alt="hims ss.png" width="968" height="139"><figcaption>HIMS sentiment and message volume as of April 17 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/c2rshi2r/message/650484205">said</a>, “Everyone is excited for a long run like previous ones to $70. Given the momentum, FDA peptide reschedule, Novo partnership, international market broadening, potential short squeeze and earnings in a month, it is going to be a hell of a rally. Huge upside potential !!”<stembedurl>https://stocktwits.com/c2rshi2r/message/650484205</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Valueiskey/message/650538005">said</a>, “Tons of upside left here…too much good news and more possible revenue for HIMS.”<stembedurl>https://stocktwits.com/Valueiskey/message/650538005</stembedurl>HIMS stock has just turned positive for the year and is now up about 0.2%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-lcid-abt-asbp-stocks-hit-52-week-lows-today/cZJUhKPRIxB">&nbsp;LCID, ABT, ASBP Stocks Hit 52-Week Lows Today: What’s Driving The Selloff?</a>

In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock's Rally May Have Plenty Of Room Left: FDA Opens Door To Testosterone Therapy 

Hims said last year that it plans to offer exclusive access to oral testosterone therapy Kyzatrex, with injectable options expected to follow.

Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies

Hims & Hers Health (NYSE:HIMS), a consumer-focused telehealth platform offering prescription and non-prescription health products, closed Thursday at $26.98, up 11.07%. The stock moved higher as investors reacted to the FDA's decision to review compounded peptide therapies. T...

<ul class="summary-bullets"><li>Health and Human Services Secretary Robert F. Kennedy Jr. said in an X post on Wednesday that the FDA will remove 12 peptides from the category of drug substances with significant safety risks.</li><li>Leerink analyst Michael Cherny views Kennedy’s announcement as a "clear positive" for Hims &amp; Hers.</li><li>The lifting of restrictions would help "fill the growth hole" the company is likely to see from the transition to commercial weight loss products, the analyst said.</li></ul>Shares of Hims &amp; Hers Health (HIMS) closed up12% on Thursday, marking its fourth consecutive day closing in the green, after the U.S. Food and Drug Administration expressed willingness to consider whether compounding pharmacies can manufacture certain peptides.Health and Human Services Secretary Robert F. Kennedy Jr. <a href="https://stocktwits.com/news-articles/markets/equity/why-is-hims-stock-rallying-after-hours/cZJtsDdRIwt">said</a> in an X post on Wednesday that the FDA will remove 12 peptides from the category of drug substances with significant safety risks. The previous categorization prohibited compounding pharmacies from making versions of it.At two meetings starting in July, independent experts at the Pharmacy Compounding Advisory Committee will rigorously evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence, the Health Secretary said, stoking investor optimism for HIMS being able to sell peptides.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around HIMS stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels. Retail chatter jumped 628% over the past day, according to platform data.A Stocktwits user said that a possible pivot to peptides will have the biggest driver of revenue growth for Hims.<stembedurl>https://www.stocktwits.com/unassuming/message/650512225</stembedurl>Another user said that the stock continues to be undervalued.<stembedurl>https://www.stocktwits.com/myleomylion/message/650511802</stembedurl>A third user said that the stars are aligned for HIMS stock with Trump not wanting to get “in the way of healthcare” and a recent agreement with Novo Nordisk to sell branded GLP-1 therapies instead of compounded treatments. &nbsp;<stembedurl>https://www.stocktwits.com/PickingTickers/message/650502697</stembedurl><h2 class="st-heading-2">Wall Street Weighs In</h2>Leerink analyst Michael Cherny views Kennedy’s announcement as a "clear positive" for Hims &amp; Hers. The lifting of restrictions would help "fill the growth hole" the company is likely to see from the transition to commercial weight loss products, the analyst told investors in a research note. Leerink believes a positive recommendation from the advisory committee would allow Hims &amp; Hers to leverage its existing peptide facility."This would not immediately translate into revenue but would seemingly be a growth avenue that HIMS would push hard on," the firm writes. Leerink has a ‘Market Perform’ rating on Hims &amp; Hers.Bank of America Securities also lifted its price target on Hims to $25 from $21, while maintaining a ‘Neutral’ rating, earlier in the day.<h2 class="st-heading-2">Hims Eyes Peptides</h2>Hims has previously expressed interest in expanding its peptide offerings. In February, the company said that it plans to work on research and development for “future categories like peptides.”“Our medical team believes certain peptide therapies hold meaningful potential in helping Americans live healthier lives, and we are actively exploring how to expand access in a way that will be aligned with FDA guidance and reflects our commitment to consumer safety, transparency, and clinical excellence,” Hims Chief Medical Office Pat Carroll said on Wednesday.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> has gained 1% over the past 12 months despite diving nearly 54% over the past six months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pbm-stock-on-track-for-best-session-on-report-of-upcoming-executive-order-on-psychedelic-ibogaine/cZJvrazRIDy">PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Closes Another Day In The Green — But Retail Sees More Upside

HIMS Stock - Retail traders are convinced that peptides will be the next key revenue driver for the online telehealth and digital pharmacy platform. 

Retail traders are convinced that peptides will be the next key revenue driver for the online telehealth and digital pharmacy platform. 


Mid Cap Stocks To Follow Now - April 16th

ProShares UltraPro Short QQQ, Hims & Hers Health, D-Wave Quantum, Direxion Daily TSLA Bull 2X Shares, AXT, Rigetti Computing, and NuScale Power are the seven Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies with a market capitaliza...

Promising Medical Stocks To Follow Now - April 16th

Abbott Laboratories, Hims & Hers Health, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

Best Healthcare Stocks To Watch Now - April 16th

Hims & Hers Health, Johnson & Johnson, UnitedHealth Group, Intuitive Surgical, Medtronic, Tempus AI, and Becton, Dickinson and Company are the seven Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly traded companies that operat...

Danaher Gears Up to Post Q1 Earnings: What Lies Ahead for the Stock?

DHR heads into Q1 results with rising bioprocessing demand and steady estimates, but cost pressures and FX headwinds could weigh on performance.

Hims & Hers Health (NYSE:HIMS) Shares Gap Up After Analyst Upgrade

Hims & Hers Health (NYSE:HIMS) Shares Gap Up After Analyst Upgrade...

HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?

Hims & Hers rolls out Benefits and taps Novo Nordisk for GLP therapies in weight-loss care as revenue grows, but margins and cash flow tighten.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Technology – AI, chips, software, cloud

Healthcare – Pharma, biotech, medical devices

Financials – Banks, payments, fintech

Energy – Oil, gas, renewables, uranium

Which sector are you most interested in deploying capital into right now?

Stocktwits

Stocktwits Polls

Hims & Hers Health Inc

Investors are optimistic that an upcoming FDA advisory meeting on peptide deregulation will unlock a massive new growth segment for the platform.

With over 30% of the float held short, traders are aggressively betting that forced covering will trigger a parabolic move toward the $40-$50 range.

Market sentiment is shifting from viewing the company as a simple telehealth app to a potential healthcare infrastructure titan with significant long-term upside.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.03	--	--	N/A
Q4 '25	$0.04	$0.08	100.62%	BEAT
Q3 '25	$0.09	$0.06	-36.40%	MISSED
Q2 '25	$0.15	$0.17	12.73%	BEAT
Q1 '25	$0.12	$0.20	65.41%	BEAT

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest HIMS News

HIMSHims & Hers Health Inc